Several innovative therapies are transforming blood sugar treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted promising choices. Retatrutide, a double GIP and GLP-1 receptor stimulant, demonstrates significant fat reduction and improved glycemic regulation. Cagrillintide, another GLP-1 stimulant, is presently